Moderna (MRNA) has surged 663% in 2026 to close at $225 on Friday, outperforming AI chipmakers to become the top-performing asset in the S&P 500. The pharmaceutical giant was down nearly 90% from its pandemic peak in mid-August before launching a rapid comeback, outstripping AI leaders during a period when equity funds faced shifting macroeconomic pressures like the Lone Pine Capital Cypress Fund erasing YTD gains following an AI stock downturn.
Cancer Vaccine Trial and Nasdaq-100 Rejoining Drive Rally
On August 19, Moderna and drugmaker Merck announced that their experimental skin cancer vaccine had successfully passed a final-stage clinical trial. The announcement followed a period where Moderna cut over 800 jobs last year due to collapsing COVID-19 vaccine sales. Moderna shares initially spiked 177% on the day of the trial news before dropping 24% the following day. Earlier in June, the stock had already gained 125% following an approval for its flu vaccine.
On Friday, Moderna officially rejoined the Nasdaq-100 index, jumping 14% in the session (8% intraday gain according to market trackers). Because more than 200 funds holding over $800 billion track the index, institutional managers were forced to buy shares. The move coincided with reports from The New York Times detailing a potential national cancer vaccine initiative slated for December. A $10,000 position in Moderna at the beginning of 2026 is now worth more than $72,000, bringing the firm's total market capitalization to approximately $89.8 billion.
Key Data Disclosure and Short Seller Caution
Despite the massive rally, full numerical results for the skin cancer trial have not yet been released. Moderna and Merck are scheduled to present detailed data on October 24 at a major cancer conference in Madrid. Marco Gerlinger, a professor at Barts Cancer Institute, stated that the results provide "proof of principle that personalised cancer vaccines work." Meanwhile, competitors BioNTech and Genentech are currently testing rival cancer treatments.
However, some market observers remain skeptical of the rapid valuation expansion. Former pharmaceutical executive Martin Shkreli publicly criticized the price move, posting that "moderna $MRNA is a great short if you can tough it out and wait 6 months." In comparison across the stock market, memory chip vendor SanDisk is up 566% year-to-date due to AI data center demand, while the broader S&P 500 index has gained roughly 14%.
Key Takeaways
- Moderna (MRNA) reached $225 on Friday, marking a 663% year-to-date gain to lead all S&P 500 stocks.
- Index inclusion in the Nasdaq-100 forced rebalancing across 200 funds managing $800 billion in assets.
- Full clinical trial results for its Merck-partnered skin cancer vaccine will be revealed on October 24 in Madrid.
- SanDisk remains the second-best S&P 500 performer with a 566% gain, while the index itself is up 14%.
Why It Matters
Moderna's dramatic turnaround demonstrates how biopharmaceutical trial milestones can temporarily outshine broader tech narratives, even during an intense artificial intelligence market surge. However, much of the recent buying momentum was mechanically driven by mandatory index-tracking inflows after the stock rejoined the Nasdaq-100. If the clinical data presented on October 24 in Madrid fails to meet heightened institutional expectations, Moderna's $89.8 billion valuation could face severe downside risk from waiting short sellers.
